

The MOH Cancer Drug List: What it means to you

In an effort to slow the rapidly escalating cost of cancer, the Ministry of Health (MOH) introduced the Cancer Drug List in 2022. Only treatments on that list can be subsidised, and can be paid for by MediShield Life and Integrated Shield Plans. Cartoonist Sonny Liew, Associate Professor Ravindran Kaneshvaran from the National Cancer Centre Singapore and Straits Times senior health correspondent Salma Khalik explain the rationale behind the MOH Cancer Drug List and how it impacts cancer treatment here. This visual explainer was commissioned by the NUS Saw Swee Hock School of Public Health and the Singapore Cancer Society.



CANCER IS THE LEADING CAUSE OF DEATH IN SINGAPORE TODAY.

CANCER 23.9%
PNEUMONIA 20%
ISCHEMIC HEART DISEASE 19.7%

ONE IN FOUR PEOPLE HERE WILL GET IT IN THEIR LIFETIME.

TREATMENT CAN BE EXPENSIVE - COSTS FOR LATE-STAGE CANCERS MAY RANGE FROM \$100,000 TO \$200,000 A YEAR.

I CAN'T AFFORD THAT!

MOST OF US WOULD NEED SUBSIDIES AND/OR INSURANCE TO HELP COVER COSTS...

BUT SOCIETY CAN!

...AND WANT TO HAVE ACCESS TO THE LATEST CANCER TREATMENTS.

BUT THIS CAN PUSH COSTS EVEN HIGHER...

CANCER DRUG SPENDING MORE THAN DOUBLED FROM \$110 MILLION TO \$275 MILLION BETWEEN 2017 AND 2021!

THIS GROWTH WAS THREE TIMES THE RATES OF NON-CANCER DRUGS!

FOR ONE THING, MANY APPROVED NEW CANCER DRUGS MAY NOT CONFER SIGNIFICANT BENEFITS COMPARED TO EXISTING ONES - BUT THEY CAN BE MUCH PRICIER.

TO GET APPROVAL, THEY JUST NEED TO SHOW THAT THEY ARE NOT INFERIOR TO OLDER DRUGS...
...AND IN SOME CASES JUST BETTER THAN PLACEBOS!

DESPITE THIS, THEY WILL BE MARKETED AND PRESCRIBED, ESPECIALLY IF THIRD PARTY COVERAGE IS GENEROUS.

DON'T WORRY, YOUR INSURANCE WILL COVER ALL YOUR BILLS!

IN FACT, GENEROUS THIRD PARTY COVERAGE ALLOWS DRUG COMPANIES AND HEALTHCARE PROVIDERS TO CHARGE MORE...

WE'VE GOT RENT AND STAFF TO PAY!
AND COST OF LIVING HERE IS HIGH!

...WHILE MAKING IT SEEMINGLY FRICTIONLESS FOR PATIENTS TO TRY OUT HIGH-COST TREATMENTS.

SUCH INCENTIVES WILL PUSH UP BOTH PUBLIC HEALTH SPENDING AND INSURANCE PREMIUMS.

LEFT UNCHECKED, WE WOULD BE SPENDING \$2.7 BILLION ON CANCER DRUGS BY 2030, SEVEN TIMES WHAT WAS SPENT IN 2019!

THE SINGAPORE GOVERNMENT HAS ALWAYS PLAYED AN ACTIVE ROLE IN SHAPING OUR HEALTHCARE SYSTEM.

WE MADE CO-PAYMENT* A KEY PRINCIPLE OF HEALTHCARE FINANCING HERE...
...TO DISCOURAGE SPENDING ON UNNECESSARY HEALTHCARE.

THAT'S MY MONEY!

*Patients must pay a percentage of their bills.

SO IN SEPTEMBER 2022, THE CANCER DRUG LIST (CDL) WAS INTRODUCED, WHICH INCLUDES ONLY TREATMENTS THAT ARE DEEMED TO BE CLINICALLY PROVEN AND COST EFFECTIVE.

CDL

TREATMENTS NOT ON THE LIST CANNOT BE COVERED BY INSURANCE, SUBSIDY OR MEDISAVE.

THIS HAS HELPED PUSH DOWN THE COSTS OF CANCER DRUGS IN THE PUBLIC SECTOR, AS DRUG COMPANIES ARE WILLING TO OFFER LOWER PRICES TO KEEP THEIR PRODUCTS ON THE CDL.

PRICES HAVE FALLEN 30% ON AVERAGE...
...AND OVER 60% IN SOME CASES!

LOWER PRICES MAKE IT POSSIBLE FOR THE GOVERNMENT TO SUBSIDISE MORE TREATMENTS...

...AND HELP PUT SOME DOWNWARD PRESSURE ON DRUG PRICES IN PRIVATE HEALTHCARE.

BUT THOUGH SUCH DEVELOPMENTS HELP TO IMPROVE SINGAPORE'S HEALTHCARE SYSTEM OVERALL...

WHAT HAPPENED??
THEY FELL THROUGH THE CRACKS!

...ANY CHANGES ON A LARGE NATIONAL SCALE WILL MEAN THAT A SMALL MINORITY MAY BE ADVERSELY AFFECTED.

THERE ARE PATIENTS WITH RARE CANCERS WHO FEAR THAT THEIR COSTLY LIFE-SAVING TREATMENTS WILL NO LONGER BE COVERED.

THE STRAITS TIMES
Brain cancer patient treated with off-label drug frets over costs when insurance coverage stops in April 2023

SUCH CASES OFTEN INVOLVE OFF-LABEL DRUG USE.

APPROVED DRUGS GET A LABEL THAT DESCRIBES WHAT THEY ARE AUTHORISED FOR.
HENCE IT'S OFF-LABEL IF THEY ARE USED FOR A PURPOSE OTHER THAN WHAT THEY ARE APPROVED FOR!
LIKE WHEN A DRUG APPROVED ONLY FOR BREAST CANCER IS USED TO TREAT COLON CANCER.

OFF-LABEL DRUG PRESCRIPTIONS CAN BE CONTENTIOUS, AS THEY ARE USED WITHOUT ROBUST EVIDENCE THAT THEY WORK.

NO, YOU CAN'T USE ANTIBIOTIC CREAM TO BRUSH YOUR TEETH!
SO THEIR USAGE MAY NOT BRING ANY BENEFITS, AND MAY EVEN BE HARMFUL.

BUT THEY ARE AN OPTION THAT DOCTORS DO TURN TO IN MANY AREAS OF HEALTHCARE.

IF THE USUAL OPTIONS FAIL, OTHER TREATMENTS THAT SEEM LOGICAL MAY BE PURSUED...
...AS WHEN TWO DIFFERENT CANCERS SHARE THE SAME MOLECULAR MARKER TARGETED BY A PARTICULAR DRUG...

THE LACK OF EVIDENCE IS ALSO PARTLY CIRCUMSTANTIAL. CLINICAL TRIALS ARE VERY EXPENSIVE TO RUN, AND IT IS DIFFICULT TO FIND ENOUGH PATIENTS WITH RARE CANCERS TO TAKE PART IN THEM.

THERE ARE JUST FEWER ECONOMIC INCENTIVES TO DEVELOP OR SEEK APPROVAL FOR DRUGS FOR RARE DISEASES.

PERHAPS THE KEY IS FINDING WAYS TO EVALUATE WHICH OFF-LABEL TREATMENTS ARE REASONABLE, AND WHICH ARE MORE RANDOM SHOTS IN THE DARK.

IN FACT, SOME OFF-LABEL TREATMENTS HAVE GOOD TRACK RECORDS, AND ARE ALREADY ON THE CDL.

18 OF THEM SO FAR!

...AND THE LIST WILL CONTINUE TO BE UPDATED AS NEW TREATMENTS AND EVIDENCE ARISE.

PLUS A RANGE OF FINANCIAL ASSISTANCE EXISTS IN THE PUBLIC SECTOR...
...SUCH AS MEDIFUND AND MEDICATION ASSISTANCE FUND PLUS FOR THOSE IN NEED.

INSURANCE COMPANIES HAVE ALSO CATEGORISED NON-CDL DRUGS BASED ON STRENGTH OF SUPPORTING EVIDENCE, SO PEOPLE WITH RIDERS* MAY HAVE TREATMENTS WITH STRONGER EVIDENCE COVERED.

I GOT AN A! WHAT ABOUT YOU?
NONE OF YOUR BUSINESS!
*Less than half of residents here opt for riders due to the higher premiums.

FOR ALL THAT, SOME WILL STILL FALL THROUGH THE CRACKS...

IT'S A VERY SMALL NUMBER!
PAPA!

...AND THEIR LOSSES MAY BE A REMINDER THAT THE TRADE-OFFS WE MAKE AS A SOCIETY CAN BE FELT IN VERY PERSONAL TERMS.

BUT ULTIMATELY, MOST ONCOLOGISTS BELIEVE THAT THE CDL WILL, IN THE LONG RUN, ALLOW THE VAST MAJORITY OF CANCER PATIENTS TO GET THE TREATMENT THEY NEED AT LOWER COST...

DO WE CONCUR?
YES!
YUP!
ER... YES.

...WHICH IS PERHAPS A KIND OF SUCCOUR WHEN FACING THE CHALLENGES PRESENTED BY THIS COMPLEX, TERRIBLE AND OFTEN FATAL DISEASE.

I'M THE EMPEROR OF ALL MALADIES!
OK, OK!

ILLUSTRATIONS AND CONCEPT: SONNY LIEW http://instagram.com/sonny_liew TEXT: SONNY LIEW AND RAVINDRAN KANESVARAN COPYRIGHT: NUS, SCS and SONNY LIEW